Bio-Rad Laboratories, Inc.
BIO · NYSE · United States · Health Care · Pharma / Biotech / Life Sci
- Coverage
- FY2016–FY2025
- History
- 10 years
- Latest filing
- 10-K · SEC EDGAR
- Reporting
- USD
- Fiscal year end
- December
- Last updated
- Feb 2026
Headline figures
Bio-Rad Laboratories, Inc. at a glance
In FY2025, Bio-Rad Laboratories, Inc. reported revenue of USD 2,583,200 thousands, EBITDA of USD 220,000 thousands, EBITDA margin of 8.5%.
| USD thousands | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 2,566,500 | 2,583,200 | |||
| EBITDA | 269,000 | 220,000 | |||
| EBITDA margin | 10.5% | 8.5% | |||
| Free cash flow | 289,600 | 374,600 | |||
| ROIC | 3.1% | 2.7% |
The full 10-year history, every line item and each formula are in the platform.
In the platform
- Stat Book — normalized and as-reported IS, BS and CF
- Up to 10 years of annual and quarterly history
- Peer benchmarking and the stock screener
- Corporate risk scorecard
- DCF model from the filed inputs
- Tearsheet and live Excel formulas